German Cancer Consortium

The last decades have brought an exponential increase in knowledge in understanding cancer. Physicians and scientists face the challenge of ensuring that patients benefit from the latest insights and developments.

Within the German Cancer Consortium (DKTK), clinicians and cancer researchers collaborate closely at eight sites in Germany with the aim to expedite novel diagnostic and treatment approaches into clinical practice. DKTK is a joint initiative involving the German Federal Ministry of Education and Research (BMBF), participating German states and the German Cancer Research Center (DKFZ). It was established in October 2012 as one of six German Health Research Centers (DZGs). The German Cancer Research Center, as the core center, works together with comprehensive cancer centers and research institutions in Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich and Tübingen to create the best possible conditions for clinically oriented cancer research, linking cutting-edge basic to translational and to clinical research. The result is a unique network of some of the strongest cancer research and treatment centers in Germany, with the main goal to discover, develop, test and apply new personalized oncology strategies.

Research programs & platforms include:

Exploiting Oncogenic Mechanisms
Molecular Diagnostics, Early Detection and Biomarker Development
Cancer Immunotherapy
Molecularly Targeted Therapy
Clinical Communication Platform
Cancer Genome Sequencing & Proteome Analysis Platform